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Abstract
Background: Genetic variants at the vitamin D receptor (VDR) locus are associated with asthma
and atopy. We hypothesized that polymorphisms in other genes of the vitamin D pathway are
associated with asthma or atopy.
Methods: Eleven candidate genes were chosen for this study, five of which code for proteins in
the vitamin D metabolism pathway (CYP27A1, CYP27B1, CYP2R1, CYP24A1, GC) and six that are
known to be transcriptionally regulated by vitamin D (IL10, IL1RL1, CD28, CD86, IL8, SKIIP). For
each gene, we selected a maximally informative set of common SNPs (tagSNPs) using the European-
derived (CEU) HapMap dataset. A total of 87 SNPs were genotyped in a French-Canadian family
sample ascertained through asthmatic probands (388 nuclear families, 1064 individuals) and
evaluated using the Family Based Association Test (FBAT) program. We then sought to replicate
the positive findings in four independent samples: two from Western Canada, one from Australia
and one from the USA (CAMP).
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Results: A number of SNPs in the IL10, CYP24A1, CYP2R1, IL1RL1 and CD86 genes were modestly
associated with asthma and atopy (p < 0.05). Two-gene models testing for both main effects and
the interaction were then performed using conditional logistic regression. Two-gene models
implicating functional variants in the IL10 and VDR genes as well as in the IL10 and IL1RL1 genes
were associated with asthma (p < 0.0002). In the replicate samples, SNPs in the IL10 and CYP24A1
genes were again modestly associated with asthma and atopy (p < 0.05). However, the SNPs or the
orientation of the risk alleles were different between populations. A two-gene model involving IL10
and VDR was replicated in CAMP, but not in the other populations.
Conclusion: A number of genes involved in the vitamin D pathway demonstrate modest levels of
association with asthma and atopy. Multilocus models testing genes in the same pathway are
potentially more effective to evaluate the risk of asthma, but the effects are not uniform across
populations.
Background
Asthma is a heterogeneous respiratory disease character-
ized by chronic inflammation of the airways associated
with recurrent symptoms that range from mild to debili-
tating [1]. Asthma is in large part attributable to genetic
factors [2]. However, identifying the causal genes has been
a daunting task due to the inherent complexity of the dis-
ease as well as methodological issues related to finding
genes of complex diseases [3]. The emerging picture from
the literature suggests hundreds of genes are associated
with asthma or asthma-related phenotypes [4,5]. Major
efforts are currently underway to validate these genes in
larger populations as well as to identify novel genes using
new technology-driven approaches such as genome-wide
single-nucleotide-polymorphism (SNP) association stud-
ies [6-8].
The innate and adaptive immune systems play an impor-
tant role in the pathogenesis of asthma. Many genes
involved in inflammation and immunoregulation path-
ways have been associated with asthma [3]. The immune
system is complex in nature with multiple redundant and
interfering pathways. Recently, the vitamin D pathway has
emerged as a new pathway contributing to the outcome of
immune responses [9-12]. The vitamin D pathway has
long been recognized for its endocrine actions on bone
and mineral homeostasis. However, growing knowledge
has elucidated autocrine and paracrine roles for the vita-
min D system with respect to cell growth, proliferation
and differentiation as well as in immune regulation [13].
The biologically active form of vitamin D (1α,25-dihy-
droxyvitamin D3), also known as calcitriol, mediates its
effect by binding to the nuclear vitamin D receptor (VDR).
Upon activation, the VDR ligand/receptor complex alters
the transcription rate of many genes involved in a wide
spectrum of biological responses [14].
The hypothesis that the vitamin D pathway plays a role in
autoimmune diseases such as asthma, originates from the
identification of VDR in immunological relevant cells,
including antigen-presenting cells and activated T lym-
phocytes [15,16]. How VDR affects immune cell popula-
tions, cytokine secretion, and production is not entirely
known, but previous evidence suggests that VDR activa-
tion may cause a developmental shift of T helper (Th) cells
toward type 2 [17,18]. The hypothesis that VDR plays a
role in asthma was also reinforced by the resistance of
VDR knock-out mice to experimentally induced asthma
[19]. These mice fail to develop airway inflammation,
eosinophilia, or airway hyperresponsiveness, despite high
IgE concentration and elevated Th2 cytokines. Recently, a
functional polymorphism (FokI, rs2228570) in the VDR
gene was shown to have a functional impact on the
immune system by interfering with the signaling of tran-
scription factors important in immune-mediated diseases
such as NF-κB and NFAT [20]. Taken together, these stud-
ies clearly support VDR as a possible candidate gene for
asthma.
Two groups co-reported that genetic variants within the
VDR  gene were associated with asthma [21,22]. In a
French-Canadian founder population, Poon et al. [21]
demonstrated that six SNPs located between intron 2 and
exon 9 spanning 28 kb of the VDR gene were associated
with asthma. Linkage disequilibrium (LD) patterns within
this population revealed the presence of two blocks
(block 1 and 2) containing 3 and 4 common haplotypes,
respectively. One haplotype within each block was over-
transmitted to affected offspring. By sequencing the pro-
moter, exons and surrounding regions, they excluded
novel missense mutations that could explain the observed
association. In a second study, Raby et al. [22] found sig-
nificant associations between VDR variants and asthma in
two independent studies. They first screened seven candi-
date genes that map to the centromeric region of chromo-
some 12 in the Childhood Asthma Management Program
(CAMP) study. Only one SNP located in the VDR gene
demonstrated evidence of association with asthma. Con-
sistent with the French-Canadian population, two LD
blocks were observed, each with three common haplo-Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
Page 3 of 21
(page number not for citation purposes)
types. The 3' haplotype block in the CAMP study was sig-
nificantly associated with asthma. To exclude the
possibility that neighboring genes cause the association,
the authors genotyped 29 SNPs in a 330 kb region sur-
rounding the VDR gene. None of these SNPs were associ-
ated with asthma, leaving VDR as the most likely causal
gene. Their finding was then replicated in the Nurses'
Health Study (NHS) [22]. In that study, four of the six
genotyped SNPs within the VDR  gene were associated
with asthma. However, it should be noted that the direc-
tion of the association in NHS was opposite to the effects
seen in CAMP, but similar to the findings in the French-
Canadian population. Taken together, these data sug-
gested that the VDR locus harbors variants that contribute
to asthma, but the orientation of the risk allele is incon-
sistent across populations.
Numerous metabolic pathways are likely to play a major
role in complex diseases. It is necessary to study the com-
ponents of these pathways to gain a more comprehensive
genetic view of the susceptibility conferred by variants
located in closely related genes [23,24]. Accordingly, we
hypothesized that polymorphisms in other genes
involved in the vitamin D system are associated with
asthma or atopy.
Methods
Population
Subjects were from the Saguenay_Lac-Saint-Jean (SLSJ)
asthma study, which consists of French-Canadian families
ascertained through asthmatic probands. Probands were
included in the study if they fulfilled at least two of the fol-
lowing criteria: 1) a minimum of three clinic visits for
acute asthma within one year; 2) two or more asthma-
related hospital admissions within one year; or 3) steroid
dependency, defined by either six month's use of oral, or
one year's use of inhaled corticosteroids. A total of 1064
individuals from 388 nuclear families were included in
the present analyses. Families were included in the study
if at least one parent was available for phenotypic assess-
ment, at least one parent was unaffected, and all four
grandparents were of French-Canadian origin. Family
members were considered asthmatics if both a self-
reported history of asthma and a history of physician-
diagnosed asthma were recorded, or by clinical evaluation
following a methacholine provocation test. Skin-prick
tests were performed for 26 inhalant allergens and sub-
jects were considered atopic if they had at least one posi-
tive response (wheal diameter ≥ 3 mm at 10 min) [25].
Spirometry, methacholine challenge and IgE measure-
ments are described in detail elsewhere [21]. Table 1
presents the characteristics of the subjects. The SLSJ local
ethics committee approved the study, and all subjects gave
informed consent.
Replication samples
Data from the Canadian Asthma Primary Prevention
Study (CAPPS) study, the Study of Asthma Genes and the
Environment (SAGE) birth cohort and the Busselton
Health Study (BHS) were used to replicate the findings.
The Childhood Asthma Management Program (CAMP)
study was also used to replicate a specific gene-gene (VDR-
IL10) interaction models. The CAPPS and SAGE studies
have been described elsewhere [26]. Briefly, the CAPPS
study was initiated in 1995 to assess the effectiveness of a
multifaceted intervention program in the primary preven-
tion of asthma in high-risk infants [27,28]. High-risk
infants were identified before birth as having at least one
first-degree relative with asthma or two first-degree rela-
tives with other IgE-mediated allergic diseases. A total of
549 children and their parents forming 545 families were
enrolled in the study during the second and third trimes-
Table 1: Characteristics of the subjects in the Saguenay_Lac-Saint-Jean study.
All subjects
(n = 1064)
Probands
(n = 210)
Affected members
(n = 320)
Unaffected members
(n = 534)
Age (years) 39.7 ± 22.1 17.6 ± 9.4 40.0 ± 19.5 48.3 ± 21.1
Male: Female ratio 0.80 0.86 0.68 0.85
Mean age of onset (years) 16.5 ± 17.0 7.4 ± 7.6 22.3 ± 18.7 NA
FEV1 (% predicted) 94.1 ± 19.8 92.5 ± 16.1 88.9 ± 23.2 99.1 ± 17.2
PEFR (%) 6.4 ± 4.6 7.3 ± 4.2 7.4 ± 5.9 5.0 ± 2.9
PC20 (mg/ml) 21.1 ± 24.9 5.1 ± 8.5 8.8 ± 15.4 39.4 ± 24.9
Serum IgE (mg/L) 452.7 ± 1619.2 720.3 ± 1919.9 531.4 ± 1960.8 244.8 ± 1005.9
Atopy (n) 593 (56.3%) 171 (81.8%) 218 (69.2%) 204 (38.6%)
Smoking Status (n)
Never 551 (52.6%) 173 (84.0%) 154 (48.7%) 224 (42.7%)
Ex-smoker 291 (27.8%) 11 (5.3%) 100 (31.7%) 180 (34.3%)
Smoker 205 (19.6%) 22 (10.7%) 62 (19.6%) 121 (23.1%)
Values are means ± SD for quantitative variables.
FEV1, Forced expiratory volume in one second; PC20, Concentration of methacholine inducing a 20% fall in FEV1; PEFR, Peak expiratory flow rate 
(morning-evening variation).Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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ter of pregnancy. The children were followed since birth
and were assessed by a pediatric allergist for the presence
of asthma and allergies. Atopy was defined by skin-prick
test. A total of 16 allergens were tested and the diagnosis
was positive if at least one wheal ≥ 3 mm than the negative
control was observed. Children with 7 year follow-up data
and DNA were included in the current study (380 chil-
dren/families). The SAGE study is a population-based
cohort of 16,320 children born in the province of Mani-
toba, Canada, between January 1, 1995 and December 31,
1995. Parents of these children were first survey by mail in
2002. A subset of children was then invited to join the
study at age 8-10 years. This subset included children with
parent-declared asthma and children without asthma. A
total of 723 families were recruited into the study. All
recruited children underwent clinical assessment of
asthma by a pediatric allergist. Skin prick testing for 16
allergens was used to define atopy. In the two latter stud-
ies (SAGE and CAPPS), children affected with asthma/
atopy and their parents were genotyped and analysed in
trios. In contrast, the BHS was analysed using a case-con-
trol design. This study comprised a series of six cross-sec-
tional health surveys that took place every three years
from 1966 to 1981 in all adults and children residing in
the Shire of Busselton, Western Australia and a follow-up
study of all previous participants (residing within and
outside this Shire) in 1994/1995. Busselton is a coastal
town in the South West region of Western Australia with a
population that is predominantly of European origin. In
the present case-control study, all subjects (n = 1395, 751
controls and 644 cases) who attended both the 1981 and
the 1994 survey and who had a diagnosis of asthma as
well as available DNA were included. Subjects were con-
sidered to have asthma if they answered yes to the ques-
tion "Has your doctor ever told you that you had asthma/
bronchial asthma?" in a written questionnaire at either
survey. Subjects were considered controls if they answered
no at both surveys. Skin prick testing for 12 allergens was
used to define atopy. Finally, CAMP is a multicentered
North American clinical trial designed to investigate the
long-term effects of inhaled anti-inflammatory medica-
tions in children with mild to moderate asthma [29,30].
A total of 1625 individual members of 428 non-Hispanic
white nuclear families were included in the present analy-
ses. This represents the subset non-Hispanic with CAMP
families with available SNP genotype data at both the
VDR and IL10 loci. The diagnosis of asthma was based on
a methacholine provocation test and one or more of the
following criteria for at least 6 months in the year before
recruitment: 1) asthma symptoms at least two times per
week, 2) at least two uses per week of an inhaled bron-
chodilator, and 3) daily asthma medication. A local ethics
committee approved the protocol independently in each
study. Written informed consent was obtained from all
study participants.
Gene selection
Eleven candidate genes were chosen for this study. Figure
1 is a cartoon of the vitamin D pathway that illustrates the
implication of each gene selected. Briefly, genes encoding
key components of the vitamin D pathway were chosen,
which include: enzymes responsible for the activation and
inactivation vitamin D (CYP27A1, CYP27B1, CYP2R1
and CYP24A1) [31,32]; the vitamin D binding protein
(GC) that binds to vitamin D and its plasma metabolites
and transports them to target tissues; SKIIP, also known as
NCoA62/SKIP, that serves as a coactivator a vitamin D-
mediated transcription [33]; and five revevant genes for
asthma that are known to be transcriptionally regulated
by vitamin D (IL10, IL1RL1, CD28, CD86 and IL8) [14].
SNP selection
SNPs were selected using the CEPH genotype dataset from
phase 1 of the International HapMap project [34]. The
genotype data were downloaded from the genomic region
covering ten kilobases up- and downstream of each gene.
A maximally informative set of SNPs was selected using a
pairwise tagging algorithm described by Carlson et al.
[35]. A Perl program, called ldSelect http://droog.gs.wash
ington.edu/ldSelect.html, was used to select the SNPs in
each gene. Briefly, this program analyzes the pattern of LD
between SNPs and forms bins of SNPs in LD based on an
r2 threshold. The algorithm ensures that all pairwise LD
values between SNPs in the same bin exceed the r2 thresh-
old. Accordingly, any SNP in a bin can serve as a proxy
(tagSNP) for all other SNPs in the same bin. Only one tag-
SNP needs to be typed per bin. At this level, nonsynony-
mous SNPs genotyped in the HapMap dataset were
prioritized using the "-required" option. Similarly, some
SNPs were prioritized based on the type of variation (A/T,
C/T, etc) to meet the genotyping technology requirement.
The minor allele frequency and the r2 thresholds were set
at 0.05 and 0.8, respectively, using the "-freq" and "-r2"
options. Known nonsynonymous SNPs or functional var-
iants not genotyped in the HapMap dataset were also
selected for genotyping. Selected SNPs and their character-
istics are shown in additional file (see Additional file 1).
The location of SNPs relative to the gene structure is illus-
trated in Additional file 2.
Genotyping
In the SLSJ study, a total of 87 SNPs were genotyped using
the SNP stream®  UHT technology [36]. Primers were
designed using FastPCR version 3.8.78 for multiplex PCR
[37]. Single base extension primers were designed using
Autoprimer.com (Beckman Coulter). The protocol and
reaction conditions were performed in accordance with
the manufacturer [36]. SNPs were genotyped in different
panels that were organized by grouping SNPs with the
same type of variation (A/T, C/T, etc) and by respecting
the 12-plex maximum capacity of the system. For the rep-Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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lication studies (CAPPS, SAGE and BHS), 52 SNPs located
in five genes were genotyped using the Illumina Golden-
Gate assay [38] as part of a larger SNP genotyping panel
http://www.genapha.ca. SNP genotypes in CAMP availa-
ble from prior analyses were generated for VDR [22] and
IL10 [39] using the MassARRAY platform (Sequenom, San
Diego, CA) and SNaPShot (Applied Biosystems, Forrest
City, CA), respectively, as previously described.
Statistical analyses
Mendelian inheritance incompatibilities were inspected
using Pedmanager version 0.9 and Hardy-Weinberg equi-
librium was evaluated using a χ2 test among parents. For
the SLSJ, CAPPS and SAGE studies the Family Based Asso-
ciation Test (FBAT) program was used to test association
with single SNPs [40]. All tests were performed with an
additive model using the empirical variance-covariance
estimator that adjusts for the correlation among sibling
genotypes and for multiple nuclear families within a sin-
gle pedigree. The FBAT test provides a Z-statistic with the
Genes involved in the vitamin D pathway Figure 1
Genes involved in the vitamin D pathway. Vitamin D3 comes from the diet but is mostly produced in the skin by the pho-
tolytic cleavage of 7-dehydrocholesterol. From vitamin D3, two enzymatic activation steps are required to produce the biolog-
ically active form of vitamin D [1α,25-(OH)2 D3]. CYP27A1 and CYP2R1 genes encode enzymes with 25-hydroxylase activity 
that catalyze the C-25 hydroxylation of vitamin D3. A final activation enzyme encoded by CYP27B1 subsequently catalyzes the 
rate-limiting C-1 hydroxylation step in 1α,25-(OH)2 D3 synthesis. The later enzyme is tightly-regulated in the kidney by calcium 
homeostatic signals, but also strongly induced by immune inputs (e.g. TLR signaling) in many cells of the immune system [12] 
(not depicted). The active form of vitamin D, 1α,25-(OH)2 D3 (orange triangle), is then transport to vitamin D target cells by 
the vitamin D binding protein (encoded by the GC locus) or is metabolically inactivated by the 24-hydroxylase enzyme 
(encoded by the CYP24A1 locus). In vitamin D target cells, 1α,25-(OH)2 D3 translocates to the nucleus and binds to the vitamin 
D receptor (VDR). The ligand/receptor complex binds vitamin D response element (VDRE) located in the promoter region of 
target genes. The DNA-bound complex interacts with nuclear coregulators, such as SKIIP [33], and alters the rate of gene 
transcription. Five genes having a VDRE or/and being transcriptionally regulated by vitamin D stimulation are shown (blue 
square). Genes selected for genotyping in the SLSJ study are circled in blue.Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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corresponding p value. A positive Z-statistic is indicative
of a high-risk allele and a negative Z-statistic is indicative
of a protective allele. In the BHS, the single SNP associa-
tions were evaluated using the Cochran-Armitage test for
trend with additive coding of alleles. Genes showing at
least one SNP with a p < 0.05 in the SLSJ collection were
considered for validation in the other populations. Our
strategy to deal with multiple testing was to replicate the
associations in independent populations instead of using
an adjusted p value. LD values were evaluated using the r2
metrics and calculated with Haploview 3.32 [41]. Power
calculations for the four study populations were recently
described [42].
Gene-gene interactions were evaluated for asthma and
atopy using a multilocus analysis method following the
framework described in Millstein et al. [23]. This strategy
is based on likelihood-ratio tests that used a log-additive
coding scheme, where genotypes aa, Aa, and AA are coded
as 0, 1, and 2, respectively. Briefly, the analyses were per-
formed in two stages. In stage one, single SNP tests of
associations were evaluated by contrasting the null
hypothesis of no association with the alternative hypoth-
esis. The threshold for significance for stage one of the
gene-gene interaction tests was then adjusted for multiple
testing using the Bonferroni correction. In stage two, a full
two-gene interaction model, including the two main
effects and the interaction term, was tested against the
reduced model that includes only the main effects that
were declared significant in the first stage, if any. This
strategy avoids retesting the same effects detected in stage
one. While the framework of Millstein et al. [23] was
described for a case-control dataset, it can easily be
adapted to a case-parent design by following the case/
pseudocontrol design described by Cordell et al. [43],
where each case is matched with three pseudocontrols
derived from the untransmitted parental alleles. Follow-
ing this, conditional logistic regression is used to assess
the significance of the main and interaction terms. Since
transmission to multiple affected siblings cannot be
assumed to be independent events, and since the families
in our sample may contain more than one case, robust
estimates for the variance and Wald tests were used
instead of likelihood ratio tests for the SLSJ, CAPPS and
SAGE studies. Considering the number of SNPs geno-
typed in genes involved in the vitamin D pathway, a total
of 5003 two-gene interaction models were evaluated.
Post hoc analyses were performed with the combined data-
set (SLSJ, CAPPS, SAGE, and BHS). Tests of association
were performed using the likelihood method imple-
mented in UNPHASE v3.0.10 [44], which allow data from
family studies and case-control individuals to be analyzed
together.
Results
Results from the SLSJ population
Additional file 1 presents the 87 genotyped SNPs and
their characteristics in the SLSJ study. Two SNPs failed the
assay design including one in the CD86 gene (rs1915087)
and another in the GC gene (rs1491711). Both of these
SNPs are singletons and are not tagging other SNPs in the
genes. A third SNP (rs8176353) located in the CYP27B1
gene was monomorphic. Additional file 1 also showed
the minor allele frequencies for a reference population
(CEPH from HapMap) and for the SLSJ study. In most
cases, the minor allele frequencies were very similar
between the two populations with a mean difference of
2% and the largest difference was 16% for SNP rs4308217
located in the CD86  gene. After Bonferroni correction,
only one SNP was out of Hardy-Weinberg equilibrium
(see Additional file 1). This SNP (rs4809960) is a single-
ton in the CYP24A1 gene and was removed from further
analyses. Accordingly, a total of 83 SNPs were tested for
association with asthma and atopy. Additional file 2
shows the exon-intron structure of each gene and the loca-
tion of genotyped SNPs.
The overall distribution of single marker FBAT association
tests shows a greater number of small p values for asthma
compared to what was expected by chance (see Additional
file 3). Results for genes with at least one significant p
value for asthma and atopy are illustrated in Figure 2
(results for all genes are illustrated in Additional file 2).
The details of these tests are shown in Table 2 for SNPs
having at least one p value < 0.1 for asthma or atopy
(FBAT results for all SNPs can be found in Additional file
4). Five SNPs in the IL10 gene, three located in the pro-
moter (rs1800872, rs1800871, rs1800896), one in intron
1 (rs3024490), and the other located in the 3' region
(rs4844553) were significantly associated with asthma.
Three of them (rs1800871, rs1800872, and rs3024490)
were in tight LD (r2 > 0.97), while the others were in low
to modest LD (Figure 3). Haplotype analysis for the three
tightly linked SNPs revealed the presence of only two hap-
lotypes with an allele frequency above 1% in the SLSJ pop-
ulation. The TAA haplotype had a frequency of 0.268 and
was overtransmitted to asthma patients (p = 0.024), while
the CCC haplotype had a frequency of 0.726 and was
undertransmitted (p = 0.013). Four out of the eight geno-
typed SNPs in the CYP24A1 gene were also modestly asso-
ciated with asthma or atopy (range of p values = 0.051 to
0.015). The two intronic SNPs associated with atopy
(rs912505 and rs927650) were in modest LD (r2 = 0.36)
and the two SNPs associated with asthma (rs2248359 and
rs8124792) located in the promoter and the 3' region of
the gene were in complete equilibrium (r2 = 0) (Figure 3).
Three intronic SNPs in the IL1RL1 gene were also associ-
ated with asthma. Two of them (rs1420089 and
rs1861245) were in modest LD (r2 = 0.28) and the thirdRespiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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Table 2: Single SNP association results for asthma and atopy in the Saguenay_Lac-Saint-Jean study.
Asthma Atopy
Gene SNP Allele Allele frequency # of families* Z P value Allele frequency # of families* Z P value
IL10 rs4844553 C 0.94 39 2.10 0.036 0.94 33 0.15 0.881
T0 . 0 6 3 9 - 2 . 1 0 0.036 0.06 33 -0.15 0.881
rs3024490 A 0.28 105 2.42 0.016 0.28 94 0.80 0.423
C 0.72 105 -2.42 0.016 0.72 94 -0.80 0.423
rs1800872 A 0.28 105 2.42 0.016 0.28 94 0.80 0.423
C 0.72 105 -2.42 0.016 0.72 94 -0.80 0.423
rs1800871 C 0.71 95 -2.52 0.012 0.71 84 -1.22 0.221
T 0.29 95 2.52 0.012 0.29 84 1.22 0.221
rs1800896 C 0.46 117 -2.47 0.014 0.46 101 -1.49 0.137
T 0.54 117 2.47 0.014 0.54 101 1.49 0.137
IL1RL1 rs950880 A 0.39 126 1.73 0.084 0.39 105 1.64 0.100
C 0.61 126 -1.73 0.084 0.61 105 -1.64 0.100
rs1420089 C 0.18 72 -2.14 0.033 0.18 60 -0.21 0.832
T 0.82 72 2.14 0.033 0.82 60 0.21 0.832
rs1946131 C 0.92 53 -2.44 0.015 0.92 42 -1.96 0.050
T 0.09 53 2.44 0.015 0.09 42 1.96 0.050
rs1921622 C 0.54 75 -1.65 0.099 0.54 65 -1.39 0.165
T 0.46 75 1.65 0.099 0.46 65 1.39 0.165
rs1861245 A 0.43 101 -2.14 0.032 0.43 74 -1.19 0.235
G 0.57 101 2.14 0.032 0.57 74 1.19 0.235
CD28 rs6435203 C 0.34 120 -1.97 0.049 0.34 104 -1.17 0.243
T 0.67 120 1.97 0.049 0.67 104 1.17 0.243
CYP27A1 rs4674338 C 0.60 96 1.85 0.064 0.60 82 1.72 0.085
T 0.41 96 -1.85 0.064 0.41 82 -1.72 0.085
CD86 rs2715267 A 0.64 102 -1.82 0.069 0.64 91 -2.86 0.004
C 0.37 102 1.82 0.069 0.37 91 2.86 0.004
rs2715273 A 0.82 79 1.75 0.081 0.82 65 1.67 0.096
T 0.18 79 -1.75 0.081 0.18 65 -1.67 0.096
rs6805035 A 0.88 51 1.74 0.083 0.88 43 1.43 0.154
C 0.12 51 -1.74 0.083 0.12 43 -1.43 0.154
rs2332096 A 0.46 117 -1.39 0.164 0.46 108 -1.79 0.074
C 0.54 117 1.39 0.164 0.54 108 1.79 0.074
CYP2R1 rs11023374 C 0.33 105 2.38 0.017 0.33 88 1.33 0.183
T 0.67 105 -2.38 0.017 0.67 88 -1.33 0.183
CYP24A1 rs8124792 C 0.95 22 2.18 0.030 0.95 24 1.89 0.058
T0 . 0 5 2 2 - 2 . 1 8 0.030 0.05 24 -1.89 0.058
rs927650 C 0.55 108 -1.65 0.100 0.55 91 -1.95 0.051
T 0.45 108 1.65 0.100 0.45 91 1.95 0.051
rs912505 C 0.29 89 -1.63 0.104 0.29 80 -2.44 0.015
T 0.71 89 1.63 0.104 0.71 80 2.44 0.015
rs2248359 C 0.58 112 2.15 0.032 0.58 97 0.56 0.577
T 0.42 112 -2.15 0.032 0.42 97 -0.56 0.577
*Number of informative families to conduct the test.
P values < 0.05 are shown in bold.Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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one (rs1946131) showed no LD with the other (Figure 3).
Also worth mentioning is a SNP (rs2715267) in the pro-
moter region of the CD86 gene that was significantly asso-
ciated with atopy (p = 0.004). A trend for this SNP was
also observed for asthma (p = 0.069). Finally, one SNP
(rs11023374) in intron 2 of the CYP2R1 gene was associ-
ated with asthma (p = 0.017). LD plots for all genes are
illustrated in Additional file 5.
Interaction among functionally related genes may not be
surprising. Hence, all possible two-gene interactions were
tested for asthma in the SLSJ study for the 11 genes under
study plus the VDR gene (Figure 4). Two concentrated
spots of significant two-gene models for asthma are
observed in this figure. The one at the bottom represents
two-gene models involving SNPs in the IL10 and VDR
genes. The second spot located in the center of Figure 4
represents two-gene models involving SNPs in the IL10
and IL1RL1 genes. Multiple two-gene models were also
significant between SNPs in the IL10 and CD86 genes.
Additional file 6 shows the two-gene models for atopy in
the SLSJ study. Overall, gene-gene interactions were mod-
est for atopy.
To understand the impact of these two-gene models on
the risk of asthma, the genotype by genotype odds ratio
matrix was calculated and some representative and most
significant two-gene models are illustrated in Figure 5.
Figure 5a, b and 5c show two-gene models between SNPs
in the IL10 and VDR genes. Figure 5a shows that the risk
of having asthma is similar for carriers of two rare IL10
alleles irrespective of the VDR genotypes. However, the
risk increases with the increasing number of common
IL10 alleles for individuals who are homozygous for the
common VDR allele. In contrast, the risk tends to decrease
with the increasing number of common IL10 alleles for
individuals who are homozygous for the rare VDR allele.
Figure 5b shows that the risk of asthma increases with the
Genetic association of SNPs in the vitamin D pathway genes with asthma and atopy in the SLSJ study Figure 2
Genetic association of SNPs in the vitamin D pathway genes with asthma and atopy in the SLSJ study. Only 
genes with a least one significant p value (p < 0.05) are illustrated. Each subfigure presents the result of one gene. The top line 
indicates the gene name and symbol. The upper part of each subfigure shows the exon-intron structure of the gene and the 
localization of the genotyped SNPs. The coding exons are shown in black and the untranslated regions are shown in grey. The 
lower part of each subfigure illustrates the association results for asthma (solid circles) and atopy (open circles). The x-axis 
shows the localization of the gene and SNPs on NCBI Human Genome build 35. The y-axis shows the FBAT empirical p values 
on a log10 scale. The lower and upper dashed lines represent p value thresholds of 0.05 and 0.001, respectively. The upper and 
lower parts of each subfigure are shown on the same scale.Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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number of rare IL10 alleles, but the effect is greater with
an increasing number of common alleles at the VDR
locus. Figure 5a and 5b show representative interactions
between SNPs located in the promoter region of IL10 and
the 3'UTR region of VDR. However, more complex inter-
actions between these two genes were observed between
SNPs located in the 3'UTR region of both genes. Figure 5c
shows that the effect of the IL10 rare allele goes in the
opposite directions depending on whether subjects are
homozygous for the common or the rare VDR alleles. Fig-
ure 5d shows a representative interaction between pro-
moter polymorphisms in the IL10  gene and
nonsynonymous SNPs located in the IL1RL1 gene. In this
model, the rare IL10 alleles increase the risk, but the mag-
nitude of the effect is greater with the number of rare alle-
les at the IL1RL1 gene. Figure 5e shows a representative
interaction between promoter polymorphisms in the IL10
and CD86 genes. In this model, the risk of asthma is sim-
ilar for carriers of two common CD86 alleles irrespective
of the IL10 genotypes, however, the risk increases addi-
tively with the number of rare alleles in the two genes.
Replication samples
For all the single SNP associations observed in the SLSJ
population, the statistical significance was modest and
did not survive multiple correction procedures. Accord-
ingly, an effort was made to replicate these findings in
three additional studies. A comprehensive set of tagging
SNPs in the IL10, CYP24A1, IL1RL1, CD86, and CYP2R1
genes plus the significant (p < 0.05) SNPs in the SLSJ study
were genotyped in the CAPPS, SAGE and BHS studies.
Table 3 shows SNPs with at least one p value < 0.05 for
asthma or atopy in the three studies as well as SNPs with
p value < 0.05 in the SLSJ study. Complete results for the
Linkage disequilibrium (LD) plots surrounding five genes involved in the vitamin D pathway in the SLSJ study Figure 3
Linkage disequilibrium (LD) plots surrounding five genes involved in the vitamin D pathway in the SLSJ study. 
The LD plots were generated by Haploview 3.32 [41]. Gene symbols are indicated at the top of each graph. The top horizontal 
bar illustrates the location of SNPs on a physical scale. The color of squares illustrates the strength of pairwise r2 values on a 
black and white scale where black indicates perfect LD (r2 = 1.00) and white indicates perfect equilibrium (r2 = 0). The r2 LD 
value is also indicated within each square. Blocks are defined using the Gabriel et al [71] definition. Failed and monomorphic 
SNPs as well as SNPs not in Hardy-Weinberg equilibrium are not illustrated.
  
CYP24A1  IL10 CYP2R1
CD86  IL1RL1 Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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Figure 4 (see legend on next page)Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
Page 11 of 21
(page number not for citation purposes)
replicate samples can be found in Additional file 7. For
IL10, none of the SNPs associated with asthma in the SLSJ
study were significant in the other studies except the pro-
moter polymorphism rs1800896, with a marginal p value
of 0.022 in CAPPS. However, the C allele that was protec-
tive in the SLSJ study was the risk allele in the CAPPS
study. The direction of the risk allele in the SAGE study
was similar to the one observed in the SLSJ, but the effect
was not significant. Similar flip-flop phenomena were
observed between the SAGE and CAPPS studies for SNPs
that were not significant in the SLSJ study. Two SNPs in
tight LD, rs3024498 located in the 3'UTR and rs3024492
located in intron 3, showed p values > 0.01 in both repli-
cate samples, but the orientation of the risk allele was
reversed. For most IL10 SNPs, it was noticeable that the
orientation of the risk alleles is in agreement between the
SLSJ and SAGE studies and in the opposite direction for
CAPPS. No SNP in the IL10 gene was significantly associ-
ated with asthma or atopy in the BHS. Taken together, sig-
nificant associations in the IL10 gene were observed in
three studies. However, different SNPs were associated in
different populations and the direction of the risk allele in
the CAPPS study was reversed compared with the SLSJ and
SAGE studies.
The associations observed for the IL1RL1  and  CYP2R1
genes in the SLSJ study were not validated in the replica-
tion samples (Table 3). No other SNP in the IL1RL1 gene
was associated with asthma or atopy in the replication
studies except a non-synonymous coding SNP
(rs1041973, Glu78Ala) that was borderline significant for
atopy in SAGE. For CYP2R1, two additional SNPs located
in the promoter and intron 1 were associated with asthma
in the BHS. However, none of these SNPs were replicated
in the other studies. For CD86, the promoter SNP
(rs2715267) that was associated with atopy in the SLSJ (p
= 0.004) could not be assessed in the other studies due to
failure of the genotyping assay. However, two other
intronic SNPs (rs9831894 and rs2332096, r2 = 0.48 in the
European HapMap data), not in LD with rs2715267, were
significantly associated with asthma in CAPPS. A different
SNP (rs9282641) located in non-coding exon 1 was sig-
nificantly associated with asthma in the BHS. This latter
SNP was not in LD with any of the three SNPs associated
with asthma in CAPPS and SLSJ. Accordingly, different
CD86  polymorphims were associated with asthma in
three populations. Finally, significant SNPs were observed
in the CYP24A1 gene in all studies. However, there was no
consistency with the SLSJ study in terms of phenotype and
orientation of the risk alleles.
The two-gene models were also performed in the replica-
tion samples for the five genes that were genotyped in
CAMP, SAGE and BHS. The significant two-gene models
involving  IL10  and  VDR  as well as IL10  and  IL1RL1
observed in the SLSJ study is not replicated in the CAPPS,
SAGE and BHS. It should be noted that the sample sizes
in the SAGE and CAPPS studies limit our ability to repli-
cate the findings. For example, the number of cases con-
tributing to the two-gene model involving IL10-
rs1800896 and VDR-rs1544410 (Figure 5a) was approxi-
mately halved in SAGE and reduced to a quarter in CAPPS
compared with the SLSJ study. However, even with similar
power, the significant two-gene models observed in the
SLSJ are not replicated in the BHS (see Additional file 8).
Taken together, none of the significant two-gene models
observed in the SLSJ study were properly replicated in
CAPPS, SAGE and BHS.
The significant two-gene models involving IL10 and VDR
were also tested in the CAMP study. A different panel of
SNPs was genotyped in CAMP and some of the two-gene
models are significant (p < 0.05). The most significant
two-gene models is observed between VDR-rs7975232
and  IL10-rs1800896 (Wald test p = 0.018) or IL10-
rs1800872 (Wald-test p = 0.016). Figure 6 shows the com-
parison of two-gene models observed in the SLSJ and
CAMP studies. VDR-rs1544410 is not genotyped in
CAMP, but rs7975232 was in moderately high LD with it
(D' = 1.0 and r2 = 0.59, based on the HapMap CEU geno-
Two-gene model analyses on asthma in the SLSJ study for genes involved in the vitamin D pathway Figure 4 (see previous page)
Two-gene model analyses on asthma in the SLSJ study for genes involved in the vitamin D pathway. The plot 
illustrates the p values for single SNP association and all possible two-SNP combinations. Each line represents a SNP listed at 
the left of the figure. Each column represents a SNP listed in the same order but from left to right. The white horizontal and 
vertical lines break up the figure by genes. Gene names are indicated at the right of the figure. P values are illustrated using the 
following color scheme: grey, p > 0.05; blue, 0.05 > p > 0.01; yellow, 0.01 > p > 0.001; orange, 0.001 > p > 0.0001, red, 0.0001 
> p > 0.00001. The squares forming the diagonal (upper-left to lower-right) depict p values for single SNP association based on 
a Wald test (see materials and methods). Two-gene models for SNPs located in the same gene were not assessed and were 
not coloured, which created the large white square patterns along the diagonal. Illustrated above the diagonal are p values for 
the interaction term only, which are the results of Wald tests contrasting the full model (two main effects and the interaction) 
to the reduced model (two main effects only). Illustrated below the diagonal are p values testing the full model (two main 
effects and the interaction) against a reduced model that is conditional on single SNPs declared significant when taken individu-
ally, if any (see materials and methods). White squares illustrate tests for which the model failed to converge.Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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Combined genotypic effects of selected two-gene models on asthma in the SLSJ study Figure 5
Combined genotypic effects of selected two-gene models on asthma in the SLSJ study. Each subfigure illustrates 
the risk of asthma according to two SNPs located in different genes. The genes and SNPs named are indicated above each sub-
figure representing SNP 1 and SNP 2, respectively. With two bi-allelic SNPs (3 genotypes per SNP), a 3 by 3 odds ratio matrix 
is calculated and visually represented. All risks are evaluated relative to homozygotes for the common allele at both SNPs. The 
y-axis shows the odds ratio on a log2 scale, which makes the odds ratio above and below 1 on the same visual scale. The x-axis 
indicates the genotypes for SNP number 1. By drawing a line that joins the dots representing the genotypes for SNP number 2, 
the genotypic effect of SNP number 1 can be observed on different genotypic backgrounds of SNP number 2. The first three p 
values come from a model testing the main effect of both SNPs and the interaction term. The Wald test p value is the result of 
the full two-gene model tested against a reduced model (see materials and methods).R
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Table 3: Single SNP association results for asthma and atopy in the replication samples.
Asthma Atopy
SAGE CAPPS BHS SAGE CAPPS BHS
G e n e s S N P s A l l e l eA FF a Z p A FF a Z p A F
case
AF
ctrl
X2 pA F F a Z pA F F a Z pA F
case
AF
ctrl
X2 p
IL10 rs4844553 A 0.07 25 0.96 0.336 0.05 11 0.3 0.763 0.05 0.06 1.21 0.272 0.07 35 -0.16 0.873 0.05 22 -1.88 0.061 0.05 0.06 0.12 0.729
G 0.93 25 -0.96 0.336 0.95 11 -0.3 0.763 0.93 35 0.16 0.873 0.95 22 1.88 0.061
rs3024498 A 0.78 83 3.06 0.002 0.78 40 -2.56 0.01 0.70 0.72 1.74 0.187 0.78 108 1.22 0.223 0.78 70 -0.54 0.592 0.71 0.72 0.26 0.608
G 0.23 83 -3.06 0.002 0.22 40 2.56 0.01 0.23 108 -1.22 0.223 0.22 70 0.54 0.592
rs3024492 A 0.78 81 2.89 0.004 0.78 40 -2.56 0.01 0.70 0.72 1.55 0.213 0.78 108 1.13 0.26 0.78 69 -0.75 0.453 0.71 0.72 0.20 0.655
T 0.22 81 -2.89 0.004 0.22 40 2.56 0.01 0.22 108 -1.13 0.26 0.22 69 0.75 0.453
rs3024490 A 0.28 69 0.63 0.527 0.29 34 -1.64 0.101 0.24 0.22 1.63 0.202 0.28 99 0.36 0.717 0.29 78 0 1 0.23 0.23 0.07 0.788
C 0.72 69 -0.63 0.527 0.71 34 1.64 0.101 0.72 99 -0.36 0.717 0.71 78 0 1
rs1800872 A 0.28 70 0.73 0.463 0.3 34 -1.64 0.101 0.24 0.22 1.64 0.200 0.28 98 0.46 0.649 0.3 78 -0.1 0.922 0.23 0.23 0.07 0.786
C 0.72 70 -0.73 0.463 0.7 34 1.64 0.101 0.72 98 -0.46 0.649 0.7 78 0.1 0.922
rs1800896 C 0.43 87 -1.22 0.221 0.43 40 2.29 0.022 0.50 0.50 0.02 0.889 0.43 124 -0.55 0.583 0.43 83 0.29 0.772 0.50 0.50 0.06 0.804
T 0.57 87 1.22 0.221 0.58 40 -2.29 0.022 0.57 124 0.55 0.583 0.58 83 -0.29 0.772
rs10494879 C 0.63 93 1.44 0.151 0.64 42 -2.07 0.039 0.55 0.56 0.51 0.476 0.63 127 0.08 0.938 0.64 82 -1.18 0.239 0.55 0.56 0.13 0.717
G 0.37 93 -1.44 0.151 0.36 42 2.07 0.039 0.37 127 -0.08 0.938 0.36 82 1.18 0.239
IL1RL1 rs1420089 C 0.09 39 1.41 0.16 0.09 19 -0.23 0.819 0.11 0.11 0.08 0.782 0.09 50 1.91 0.057 0.09 40 0 1 0.12 0.12 0.03 0.874
T 0.91 39 -1.41 0.16 0.91 19 0.23 0.819 0.91 50 -1.91 0.057 0.91 40 0 1
rs1041973 A 0.22 80 -0.1 0.921 0.23 35 0.16 0.876 0.22 98 -1.99 0.046 0.23 73 0.11 0.915
C 0.78 80 0.1 0.921 0.77 35 -0.16 0.876 0.78 98 1.99 0.046 0.77 73 -0.11 0.915
rs1946131 A 0.11 43 -0.3 0.768 0.1 16 -0.23 0.819 0.10 0.10 0.36 0.55 0.11 52 -1.05 0.294 0.1 37 0.78 0.435 0.10 0.09 1.61 0.205
G 0.9 43 0.3 0.768 0.9 16 0.23 0.819 0.9 52 1.05 0.294 0.9 37 -0.78 0.435
CD86 rs9282641 C 0.93 36 0.8 0.423 0.93 14 -0.78 0.439 0.89 0.92 7.34 0.007 0.93 42 0 1 0.93 35 -0.16 0.873 0.91 0.90 0.82 0.365
T 0.07 36 -0.8 0.423 0.07 14 0.78 0.439 0.07 42 0 1 0.07 35 0.16 0.873
rs9831894 G 0.42 88 -1.12 0.261 0.4 40 -2.61 0.009 0.39 0.39 0.00 0.952 0.42 124 -0.23 0.817 0.4 96 -0.26 0.792 0.39 0.40 0.21 0.645
T 0.58 88 1.12 0.261 0.6 40 2.61 0.009 0.58 124 0.23 0.817 0.6 96 0.26 0.792R
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rs2332096 G 0.57 87 -1.53 0.127 0.56 43 -2.36 0.018 0.53 0.55 0.47 0.491 0.57 129 -1.08 0.28 0.56 94 -0.92 0.357 0.54 0.54 0.00 0.958
T 0.44 87 1.53 0.127 0.44 43 2.36 0.018 0.44 129 1.08 0.28 0.44 94 0.92 0.357
CYP2R1 rs11023374 C 0.27 72 -0.63 0.532 0.27 35 0.44 0.662 0.27 0.28 0.07 0.793 0.27 91 0.38 0.703 0.27 72 1.05 0.292 0.28 0.27 0.08 0.775
T 0.73 72 0.63 0.532 0.73 35 -0.44 0.662 0.73 91 -0.38 0.703 0.73 72 -1.05 0.292
rs10500804 G 0.4 92 1.81 0.07 0.44 40 -0.41 0.68 0.41 0.44 4.25 0.039 0.4 119 0.72 0.47 0.44 94 0.81 0.421 0.42 0.43 0.30 0.582
T 0.6 92 -1.81 0.07 0.56 40 0.41 0.68 0.6 119 -0.72 0.47 0.56 94 -0.81 0.421
rs1562902 C 0.46 93 -0.83 0.405 0.42 39 -0.42 0.674 0.47 0.43 4.71 0.03 0.46 126 0.16 0.874 0.42 93 -0.62 0.538 0.46 0.43 2.38 0.123
T 0.54 93 0.83 0.405 0.58 39 0.42 0.674 0.54 126 -0.16 0.874 0.58 93 0.62 0.538
CYP24A1 rs8124792 A 0.06 30 0.17 0.862 0.08 12 -0.26 0.796 0.06 0.06 0.29 0.591 0.06 42 1.18 0.238 0.08 40 0.15 0.881 0.07 0.05 4.65 0.031
G 0.94 30 -0.17 0.862 0.93 12 0.26 0.796 0.94 42 -1.18 0.238 0.93 40 -0.15 0.881
rs927650 C 0.54 94 0.81 0.417 0.57 41 -0.69 0.492 0.55 0.50 6.75 0.009 0.54 127 0.23 0.816 0.57 10
0
0.78 0.439 0.54 0.52 0.89 0.344
T 0.46 94 -0.81 0.417 0.43 41 0.69 0.492 0.46 127 -0.23 0.816 0.43 10
0
-0.78 0.439
rs912505 A 0.75 75 0.53 0.596 0.73 29 0.69 0.493 0.78 0.79 0.41 0.521 0.75 106 0.83 0.409 0.73 86 -0.2 0.843 0.77 0.79 1.64 0.200
G 0.25 75 -0.53 0.596 0.27 29 -0.69 0.493 0.25 106 -0.83 0.409 0.27 86 0.2 0.843
rs2248359 A 0.35 87 1.04 0.296 0.44 41 1.82 0.069 0.41 0.41 0.02 0.889 0.35 133 0.54 0.588 0.44 97 2.51 0.012 0.42 0.40 1.14 0.287
G 0.65 87 -1.04 0.296 0.56 41 -1.82 0.069 0.65 133 -0.54 0.588 0.56 97 -2.51 0.012
rs2426498 C 0.87 49 -1.39 0.166 0.87 24 0.82 0.414 0.86 0.87 0.03 0.859 0.87 58 -2.14 0.032 0.87 61 0.25 0.806 0.86 0.87 0.06 0.814
G 0.13 49 1.39 0.166 0.13 24 -0.82 0.414 0.13 58 2.14 0.032 0.13 61 -0.25 0.806
rs6068821 A 0.41 95 2.32 0.021 0.45 39 0.27 0.785 0.41 0.39 1.15 0.283 0.41 126 2.24 0.025 0.45 96 1.17 0.241 0.42 0.40 1.07 0.302
G0 . 5 9 9 5 - 2 . 3 2 0.021 0.55 39 -0.27 0.785 0.59 126 -2.24 0.025 0.55 96 -1.17 0.241
CAPPS, Canadian Asthma Primary Prevention Study; SAGE, Study of Asthma Genes and the Environment; BHS, Busselton Health Study; AF, allele frequency; Fa, Number of informative families to conduct the 
test.
P values below 0.05 are shown in bold. SNPs that are significant in the SLSJ study (Table 2) are underlined as well as the allele that increases the risk in that study. Coding non-synonymous SNPs are shown in 
bold.
Table 3: Single SNP association results for asthma and atopy in the replication samples. (Continued)Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
Page 15 of 21
(page number not for citation purposes)
typing dataset). The gene-gene interaction models were
similar between the two studies. The effect of the IL10 var-
iant on asthma seemed dependent on the VDR variant.
This can be appreciated in Figure 6 by comparing the
solid, dotted and dashed lines between studies. The flip-
flop phenomenon previously observed in the VDR gene
between the SLSJ and CAMP studies [21,22] can also be
appreciated in Figure 6 (the solid line is at the top in the
SLSJ study and at the bottom in the CAMP study).
Combined analyses
Single SNP association tests and two-gene models were
tested in the combined dataset. Overall, none of the SNPs
are significantly associated with asthma or atopy after cor-
rections for multiple testing (see Additional file 9). Simi-
larly, the two-gene models for asthma and atopy were not
significant (see Additional files 10 and 11, respectively).
Discussion
We performed a genetic association study between asthma
and genes involved in the vitamin D pathway. SNPs
located in five genes, including IL10, CYP24A1, IL1RL1,
CYP2R1  and  CD86, showed modest association with
asthma or atopy in an asthma family study derived from
the Saguenay_Lac-Saint-Jean population. Exploring gene-
gene interactions in this pathway revealed significant two-
gene models that refined risk evaluation for asthma. In an
attempt to replicate these findings, we evaluated the sig-
nificant genes in two additional Canadian studies and one
Australian study. Again modest associations were
observed for the IL10,  CYP24A1  and  CD86  genes for
asthma or atopy. In general, SNPs showing association
were different between studies or the orientation of the
risk allele was reversed. Similarly, the significant two-gene
models found in the original study were not replicated in
the two additional Canadian studies and the Australian
study. However, a significant two-gene model involving
the IL10 and VDR gene was replicated in the American
study.
Overall, no genes or gene-gene interactions in the vitamin
D pathway were consistently associated with asthma or
atopy across all populations. This can be explained by
multiple factors as discussed previously [3,42]. Briefly,
asthma was defined differently between populations,
including patient self-reported, physician's diagnosis, or a
combination of clinical characteristics and objective
threshold from methacholine challenges. In addition, the
individual studies are either early or late-onset asthma.
More specific for the current study, many environmental
factors such as sun exposure and dietary vitamin D intake
may differ between studies and explained some of the
controversies and flip-flop observations. Considering the
differences among populations, our replication effort may
be more properly labeled as a descriptive study.
A number of SNPs in the IL10 gene surrounding the pro-
moter region and extending up to intron 1 were signifi-
Two-gene models on asthma involving the IL10 and VDR genes in the SLSJ and the CAMP studies Figure 6
Two-gene models on asthma involving the IL10 and VDR genes in the SLSJ and the CAMP studies. With two bi-
allelic SNPs (3 genotypes per SNP), a 3 by 3 odds ratio matrix is calculated and visually represented. The y-axis shows the odds 
ratio on a log2 scale, which makes the odds ratio above and below 1 on the same visual scale. The IL10 genotypes are illustrated 
on the x-axis. Different panels of SNPs were genotyped between the two studies and the comparison for the VDR gene is made 
with different SNPs that are in LD (D' = 1.0 and r2 = 0.59, based on the HapMap CEU genotyping dataset). In the SLSJ study, 
the risks are evaluated relative to the VDR-GG and IL10-TT genotypes. In CAMP, the risks are evaluated relative to the VDR-
CC and IL10-TT genotypes.Respiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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cantly associated with asthma in the SLSJ collection. All
these SNPs were in tight LD and most of the genetic diver-
sity at this locus was captured by only two haplotypes.
Based on functional studies [45-50], the three-SNP pro-
moter haplotypes formed by rs180096, rs1800871, and
rs1800872 have been referred as the high and low IL10-
producing haplotypes. IL10 is known as an anti-inflam-
matory cytokine [51]. Accordingly, it makes biological
sense that a low IL10-producing haplotype would be asso-
ciated with asthma, which is consistent with most of the
literature [39,52-54]. Surprisingly, none of the promoter
polymorphisms in IL10 were associated with asthma or
atopy in the SAGE and CAPPS populations with the excep-
tion of rs1800896, which was associated with asthma in
CAPPS. However, the orientation of the risk allele was
reversed compared to what was observed in the SLSJ study
and the vast majority of the scientific literature. In con-
trast, SNPs located in the 3' end of the IL10  gene
(rs3024498 and rs3024492) were associated with asthma
in the replicate samples. The functional consequences of
these SNPs are unknown but they were previously associ-
ated with serum levels of calcidiol (25-OH-D3), the pre-
hormone form of vitamin D [55], and with longitudinal
decline rate of lung function [56].
Other genes in the vitamin D pathway tested in the cur-
rent study have been previously associated with asthma or
asthma-related phenotypes. In the German Asthma Fam-
ily Study, Wjst et al. [55] identified SNPs in the IL10 gene
but also in the GC, CYP2R1 and CYP24A1 genes that were
significantly associated with asthma or IgE levels. Interest-
ingly, SNPs in these genes were also associated with serum
levels of calcidiol (25-OH-D3) and calcitriol
[1α,25(OH)2D3]. In the SLSJ population, three SNPs in
the CYP24A1 gene showed modest evidence of associa-
tion with asthma or atopy (p < 0.05). In addition, the only
CYP24A1  SNP (rs2248359) genotyped in common
between the German and SLSJ population showed a con-
sistent result with an increase risk of asthma associated
with the C allele. SNPs in the CYP2R1 gene, encoding an
enzyme implicated in earlier steps of the vitamin D meta-
bolic pathway, were also associated with asthma in both
the German and the SLSJ studies. Only one SNP in the
CD86 and CD28 genes reached significance in the SLSJ
population. The CD28 and CD86 interaction represents
an important costimulatory signaling pathway for CD4
positive T cell activation and Th2 cytokine production
[57]. The association between atopy and the CD86 pro-
moter polymorphism rs2715267 was relatively strong in
the SLSJ collection (p = 0.004). Different SNPs in the
CD86 gene were also associated with asthma in the CAPPS
and BHS studies. Thus, evidence is building to implicate
CD86 as a susceptibility gene for asthma, but independent
replications in larger population samples are required. In
contrast, the overall results for CD28 are more consistent
with the previous studies showing the lack of association
with asthma [58-60]. Many SNPs in the IL1RL1 gene were
associated with asthma in the SLSJ study. This receptor is
required for the development of an effective Th2 response
[61,62] and mediates the biological effects of IL-33 [63].
A functional promoter polymorphism (rs6543116) in the
IL1RL1 gene was previously associated with atopic derma-
titis and high total IgE levels in the sera from the same
patients [64]. More recently, a genome-wide association
scan for blood eosinophil count identified a strong asso-
ciation with an intronic SNP (rs1420101) in this gene
[65]. The same SNP was then associated with asthma in a
collection of ten different populations (7,996 cases and
44,890 controls). This SNP was not genotyped in the cur-
rent study, but rs950880 can be used as a surrogate (r2 =
0.96 based on the European HapMap data). rs950880 was
not associated with asthma or atopy in any of the four
populations evaluated in the current study. However, a
trend (p ≤ 0.10) in the same direction as the eosinophil/
asthma study [65] was observed for asthma and atopy in
the SLSJ study as well as for atopy in the BHS. Finally, the
SLSJ results do not support previous observations with the
GC and IL8 genes [55,66,67].
It is reasonable to expect interactions among functionally
related genes. In the SLSJ study, some two-gene models
were more efficient at evaluating the risk of asthma com-
pared with single SNP models. The models implicating
functional variants in the VDR and IL10 genes are partic-
ularly interesting. We previously demonstrated that
genetic variants in the VDR  gene are associated with
asthma [21]. Since the latter publication [21], we have
genotyped more SNPs in the VDR gene in the same popu-
lation and many SNPs between intron 2 and exon 9 are
associated with asthma (see Additional file 12). The
mechanism explaining this association is still unclear, but
allele-specific expression at this locus implicates the pres-
ence of genetic variants that influence VDR  expression
[68]. In fact, we observed that the highly expressed haplo-
type was overtransmitted to asthmatic individuals, while
the low expressed haplotype was undertransmitted [3].
These  VDR  haplotypes can be tagged by the SNP
rs1544410 with the G allele being associated with the
high-risk/high-expressed haplotype and the A allele being
associated with the low-risk/low-expressed haplotype. As
mentioned above, the low IL10-producing haplotype was
associated with asthma in the same population (SLSJ).
These  IL10  haplotypes can be tagged by the SNP
rs1800871 with the T allele being associated with the
high-risk/low-producing haplotype and the C allele being
associated with the low-risk/high-production haplotype.
By combining the information of both SNPs (IL10-
rs1800871 and VDR-rs1544410) we obtained the two-
gene model shown in Figure 5b and that was a significant
(p = 0.00018) predictor of the risk of asthma. In thisRespiratory Research 2009, 10:98 http://respiratory-research.com/content/10/1/98
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model, the risk of asthma increased additively with the
number of G alleles (tagging the high-risk/high-expressed
haplotype) at the VDR locus and with the number of T
alleles (tagging the high-risk/low-producing haplotype) at
the  IL10  locus. Similarly, other intriguing interactions
between plausible candidate genes were observed in the
SLSJ population, including IL10 and IL1RL1 (Figure 5d)
as well as IL10 and CD86 (Figure 5e). Although interest-
ing, the large majority of these two-gene models were not
replicated in the other populations. In the CAMP study, a
two gene-model involving IL10 and VDR variants mir-
rored the observation made in the SLSJ sample. However,
further work will be required to demonstrate the relevance
of these two-gene models in asthma.
The cascade of enzymatic reactions that lead to the bio-
synthesis of 1α,25(OH)2D3 is complex and requires the
participation of many gene products (Figure 1). It is con-
ceivable that polymorphisms in any of several genes in
this pathway could lead to differences in endogenous bio-
synthesis and bioavailability of 1α,25(OH)2D3. At a more
downstream step in the pathway, genetic variants in the
VDR itself or in genes implicated in the transcriptional
machinery, can influence the sensitivity of the
1α,25(OH)2D3 stimulus. Further downstream are tran-
scriptionally regulated genes, or vitamin responsive genes,
that mediate the broad physiological actions of
1α,25(OH)2D3. Again, polymorphisms in these genes are
prime candidates to influence the vitamin D response.
However, at this level the task is rather challenging owing
to the large number of genes regulated by 1α,25(OH)2D3
[14]. An extra layer of complexity exists, knowing that the
regulation of gene expression by 1α,25(OH)2D3 is highly
cell-specific [69,70]. Accordingly, a large number of genes
can determine the overall response to the vitamin D path-
way. With this in perspective, gene selection in the current
study was not comprehensive. On the other hand, the
results of the current study may have implications in a
wider scope than the field of asthma and asthma-related
phenotypes. SNPs associated with asthma in the vitamin
D pathway genes may influence the overall vitamin D sen-
sitivity and consequently influence many other diseases
[55].
Conclusion
Cumulative observations implicate the vitamin D path-
way in immune responses. By studying genes involved in
this pathway, we identified genetic polymorphisms mod-
estly associated with asthma and atopy in asthmatic fam-
ilies from the Saguenay_Lac-Saint-Jean region. Significant
two-gene models that include interactions between com-
ponents of the pathway were also identified. We then
attempted to replicate the findings in two additional
Canadian studies and one Australian study. Similar to the
SLSJ study, some SNPs in the IL10 and CYP24A1 genes
were modestly associated with asthma or atopy. However,
the SNPs or the orientation of the risk alleles were differ-
ent between populations. It is conceivable that the effect
of the VDR system in immune responses can be overruled
by more potent immune pathways. Accordingly, the effect
of the vitamin D pathway might be detectable only in spe-
cific environments or age-related contexts. Further studies
are warranted to confirm the single SNP and the multilo-
cus models associated with asthma in the current study.
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and the untranslated regions are shown in grey. The lower part of each 
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atopy (open circles). The x-axis shows the localization of the gene and 
SNPs on NCBI Human Genome build 35. The y-axis shows the FBAT 
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physical scale. The color of squares illustrates the strength of pairwise r2 
values on a black and white scale where black indicates perfect LD (r2 = 
1.00) and white indicates perfect equilibrium (r2 = 0). The r2 LD value is 
also indicated within each square. Blocks are defined using the Gabriel et 
al [71] definition. Failed and monomorphic SNPs as well as SNPs not in 
Hardy-Weinberg equilibrium are not illustrated.
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Genetic association between SNPs in the vitamin D receptor gene and 
asthma in the SLSJ study. The upper part of the figure shows the exon-
intron structure of the gene and the localization of the genotyped SNPs. 
The coding exons are shown in black and the untranslated regions are 
shown in grey. The lower part of the figure illustrates the association 
results for asthma. The x-axis shows the localization of the gene and SNPs 
on NCBI Human Genome build 35. The y-axis shows the FBAT empirical 
p values on a log10 scale. The lower and upper dashed lines represent p 
value thresholds of 0.05 and 0.001, respectively. The upper and lower 
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